IBRXHealthcare · BiotechnologyThe 4 Wall Street analysts covering ImmunityBio, Inc. hold a median 12-month price target of $12 — +57.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 54 of 100 as at 8 Aug 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores ImmunityBio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (89): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Issuance (7): The company has been issuing shares or taking on financing, diluting existing holders.
The rank is the raw material. Whether the rules would actually own ImmunityBio, Inc. — and when they’d sell — is the membership.
The bullish and bearish analyst opinions on IBRX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +57.1% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 2 June 2026 | HC Wainwright & Co. | Reiterates | Buy | $15 |
| 21 May 2026 | BTIG | Reiterates | Buy | — |
| 20 May 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 5 May 2026 | D. Boral Capital | Maintains | Buy | — |
| 21 Apr 2026 | D. Boral Capital | Maintains | Buy | — |
| 8 Apr 2026 | D. Boral Capital | Maintains | Buy | — |
| 26 Mar 2026 | D. Boral Capital | Maintains | Buy | — |
| 23 Mar 2026 | D. Boral Capital | Maintains | Buy | — |
| 17 Mar 2026 | D. Boral Capital | Maintains | Buy | — |
| 12 Mar 2026 | BTIG | Assumes | Buy | $13 |
| 9 Mar 2026 | D. Boral Capital | Maintains | Buy | — |
| 4 Mar 2026 | Piper Sandler | Reiterates | Overweight | — |
| 23 Feb 2026 | D. Boral Capital | Maintains | Buy | — |
| 23 Feb 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 19 Feb 2026 | D. Boral Capital | Maintains | Buy | — |
| 17 Feb 2026 | D. Boral Capital | Maintains | Buy | — |
| 26 Jan 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 23 Jan 2026 | BTIG | Maintains | Buy | — |
| 23 Jan 2026 | D. Boral Capital | Maintains | Buy | — |
| 20 Jan 2026 | D. Boral Capital | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 96% of US stocks
Cheaper than 6% of US stocks
Cheaper than 97% of US stocks
Cheaper than 92% of US stocks
Higher than 92% of US stocks
Higher than 84% of US stocks
Higher than 99% of US stocks
Higher than 13% of US stocks
Higher than 99% of US stocks
Higher than 95% of US stocks
Higher than 14% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. IBRX appears on the weeks it earns a place.
ImmunityBio beat Q2 earnings and revenue estimates, with record Anktiva sales and continued adoption fueling growth. The company has additional regulatory milestones ahead.
Why it matters — The earnings and revenue beat, driven by record Anktiva sales and adoption, signals strong commercial momentum and may focus watchers on upcoming regulatory milestones.
ImmunityBio reported a Q2 loss of $0.08 per share, beating the Zacks Consensus Estimate of a $0.09 loss and narrowing from a $0.10 per-share loss a year ago.
Why it matters — The narrower-than-expected loss signals improved financial performance, which IBRX watchers would view as a positive earnings surprise.
ImmunityBio reported financial and operational results for Q2 2026, with net product revenue reaching $50.7 million, up 92% year-over-year and 15% sequentially. First-half revenue rose 121% to $94.8 million, and the company said it advanced multiple regulatory and clinical programs across its immunotherapy pipeline.
Why it matters — An IBRX watcher would care because the company posted record product revenue growth while continuing to advance its immunotherapy pipeline across regulatory and clinical programs.
The Emirates Drug Establishment in the United Arab Emirates approved ImmunityBio's immunotherapy drug, ANKTIVA. The company described the move as the world's broadest bladder cancer approval.
Why it matters — The UAE approval expands ANKTIVA's regulatory reach into a new international market, broadening the drug's commercial footprint beyond the U.S.
ImmunityBio announced that the Emirates Drug Establishment of the United Arab Emirates has granted Marketing Authorization for ANKTIVA across two indications: for BCG-unresponsive non-muscle invasive bladder cancer and for metastatic non-small cell lung cancer.
Why it matters — This marketing authorization expands ANKTIVA's regulatory reach into a new international market, potentially opening a pathway for future revenue growth outside the U.S.
The 4 Wall Street analysts covering ImmunityBio, Inc. have a median 12-month price target of $12, with estimates ranging from $12 to $15. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 4 analysts covering ImmunityBio, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks ImmunityBio, Inc. 54 out of 100 across roughly 4,600 US stocks as at 8 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 8 Aug 2026, ImmunityBio, Inc. ranks 54 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (89 of 100).
No one can know that. What the data says: the median 12-month target from 4 analysts implies +57.1% from the last close, and Ticker Nerd's factor model ranks ImmunityBio, Inc. 54 out of 100 as at 8 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering ImmunityBio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IBRX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $15 over the next 12 months.
ImmunityBio, Inc. returned +217.7% over the 12 months to 7 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
ImmunityBio, Inc. is a commercial-stage biotechnology company dedicated to developing and commercializing next-generation immunotherapies that harness the body's innate and adaptive immune systems to combat cancer and infectious diseases.
The most recent item we track (Zacks Investment Research, 5 Aug 2026): "IBRX Q2 Earnings & Sales Beat Estimates on Strong Anktiva Uptake". ImmunityBio beat Q2 earnings and revenue estimates, with record Anktiva sales and continued adoption fueling growth. The company has additional regulatory milestones ahead.
ImmunityBio, Inc. is a commercial-stage biotechnology company dedicated to developing and commercializing next-generation immunotherapies that harness the body's innate and adaptive immune systems to combat cancer and infectious diseases. Its lead product, ANKTIVA (nogapendekin alfa inbakicept-pmln), is an FDA-approved interleukin-15 superagonist used in combination with BCG for treating BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ. The company operates a vertically integrated model, controlling processes from discovery and research through manufacturing and commercialization via its proprietary BioShield platform, which includes cytokine fusion proteins, cell therapies, DNA vaccines, and recombinant BCG to address supply shortages. ImmunityBio maintains a robust clinical pipeline targeting solid and liquid tumors, such as non-small cell lung cancer and glioblastoma, as well as infectious diseases. Founded in 2014 and headquartered in Morrisville, North Carolina, ImmunityBio focuses on patient-centric innovations that augment natural killer cells, T-cells, macrophages, and dendritic cells for durable immune responses.
CEO Mr. Richard Gerald Adcock · 680 employees · United States · https://immunitybio.com